DK3390403T3 - Farmakologisk sammensætning, der omfatter indole-derivater, fremgangsmåde til forberedelse og brug deraf - Google Patents
Farmakologisk sammensætning, der omfatter indole-derivater, fremgangsmåde til forberedelse og brug deraf Download PDFInfo
- Publication number
- DK3390403T3 DK3390403T3 DK16843253.2T DK16843253T DK3390403T3 DK 3390403 T3 DK3390403 T3 DK 3390403T3 DK 16843253 T DK16843253 T DK 16843253T DK 3390403 T3 DK3390403 T3 DK 3390403T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparation
- indole derivatives
- pharmacological composition
- pharmacological
- composition
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 239000008196 pharmacological composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1500520 | 2015-12-18 | ||
| PCT/EP2016/025175 WO2017102097A1 (en) | 2015-12-18 | 2016-12-10 | Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3390403T3 true DK3390403T3 (da) | 2022-08-29 |
Family
ID=58231562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16843253.2T DK3390403T3 (da) | 2015-12-18 | 2016-12-10 | Farmakologisk sammensætning, der omfatter indole-derivater, fremgangsmåde til forberedelse og brug deraf |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10668056B2 (enExample) |
| EP (1) | EP3390403B1 (enExample) |
| JP (2) | JP6929299B2 (enExample) |
| CN (1) | CN108431003A (enExample) |
| AU (1) | AU2016371541B2 (enExample) |
| CA (1) | CA3008084A1 (enExample) |
| DK (1) | DK3390403T3 (enExample) |
| EA (1) | EA039778B1 (enExample) |
| ES (1) | ES2925690T3 (enExample) |
| HK (1) | HK1257129A1 (enExample) |
| HU (1) | HUE059610T2 (enExample) |
| PL (1) | PL3390403T3 (enExample) |
| PT (1) | PT3390403T (enExample) |
| WO (1) | WO2017102097A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2925690T3 (es) * | 2015-12-18 | 2022-10-19 | Vivolux Ab | Composición farmacéutica que comprende derivados de indol, proceso para la preparación y uso de estos |
| WO2021044608A1 (ja) * | 2019-09-06 | 2021-03-11 | シミックホールディングス株式会社 | ダントロレン水性製剤及びその調製方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660737B2 (en) * | 2001-05-04 | 2003-12-09 | The Procter & Gamble Company | Medicinal uses of hydrazones |
| US20060217437A1 (en) * | 2005-03-17 | 2006-09-28 | Burmester James K | TGF-beta modulators and methods for using the same |
| WO2009035534A2 (en) * | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| BR112013024211B1 (pt) * | 2011-03-21 | 2020-12-15 | Vivolux Ab | Tratamento de tumores sólidos |
| EP2900667B1 (en) * | 2012-09-21 | 2019-06-05 | Vivolux AB | Means and method for treating solid tumours |
| ES2925690T3 (es) * | 2015-12-18 | 2022-10-19 | Vivolux Ab | Composición farmacéutica que comprende derivados de indol, proceso para la preparación y uso de estos |
-
2016
- 2016-12-10 ES ES16843253T patent/ES2925690T3/es active Active
- 2016-12-10 AU AU2016371541A patent/AU2016371541B2/en not_active Ceased
- 2016-12-10 DK DK16843253.2T patent/DK3390403T3/da active
- 2016-12-10 CA CA3008084A patent/CA3008084A1/en active Pending
- 2016-12-10 HU HUE16843253A patent/HUE059610T2/hu unknown
- 2016-12-10 WO PCT/EP2016/025175 patent/WO2017102097A1/en not_active Ceased
- 2016-12-10 PL PL16843253.2T patent/PL3390403T3/pl unknown
- 2016-12-10 US US16/061,868 patent/US10668056B2/en active Active
- 2016-12-10 CN CN201680074239.0A patent/CN108431003A/zh active Pending
- 2016-12-10 HK HK18116383.1A patent/HK1257129A1/zh unknown
- 2016-12-10 PT PT168432532T patent/PT3390403T/pt unknown
- 2016-12-10 EA EA201891027A patent/EA039778B1/ru unknown
- 2016-12-10 EP EP16843253.2A patent/EP3390403B1/en active Active
- 2016-12-10 JP JP2018550649A patent/JP6929299B2/ja not_active Expired - Fee Related
-
2021
- 2021-05-07 JP JP2021079373A patent/JP2021130673A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6929299B2 (ja) | 2021-09-01 |
| HK1257129A1 (zh) | 2019-10-11 |
| JP2019505571A (ja) | 2019-02-28 |
| CN108431003A (zh) | 2018-08-21 |
| WO2017102097A1 (en) | 2017-06-22 |
| PL3390403T3 (pl) | 2022-10-24 |
| HUE059610T2 (hu) | 2022-12-28 |
| ES2925690T3 (es) | 2022-10-19 |
| AU2016371541A1 (en) | 2018-06-07 |
| PT3390403T (pt) | 2022-09-06 |
| EP3390403A1 (en) | 2018-10-24 |
| CA3008084A1 (en) | 2017-06-22 |
| US10668056B2 (en) | 2020-06-02 |
| JP2021130673A (ja) | 2021-09-09 |
| EA201891027A1 (ru) | 2019-02-28 |
| EA039778B1 (ru) | 2022-03-14 |
| EP3390403B1 (en) | 2022-06-29 |
| US20180280366A1 (en) | 2018-10-04 |
| AU2016371541B2 (en) | 2021-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3453707T3 (da) | Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3559000T3 (da) | Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf | |
| DK3312177T3 (da) | Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme | |
| DK3486242T3 (da) | Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf | |
| DK3214081T3 (da) | Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3209308T3 (da) | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf | |
| DK3548033T3 (da) | Forbindelser og deres fremgangsmåde til anvendelse | |
| DK3363183T3 (da) | Fremgangsmåde og indretning til dynamisk protokolvalg | |
| HUE054724T2 (hu) | Mono- vagy diszubsztituált indolszármazékok dengue-vírus replikáció inhibitorokként | |
| DK2947084T3 (da) | Fem- og seks-ledet heterocyklisk forbindelse og forberedelsesmetode, farmaceutisk sammensætning og anvendelse deraf | |
| DK3271347T3 (da) | Antifungale forbindelser og fremstillingsfremgangsmåder | |
| PL3370750T3 (pl) | Połączona kompozycja pre- i probiotyków | |
| DK3404024T3 (da) | Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser | |
| DK3233111T3 (da) | Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf | |
| DK3107902T3 (da) | Forbindelser og fremgangsmåder til at hæmme fascin | |
| DK3551619T3 (da) | Sammensætninger, der omfatter methylphenidat-prodrugs, fremgangsmåder til fremstilling og anvendelse heraf | |
| DK3380525T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf | |
| DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
| DK3389669T3 (da) | Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf | |
| DK3398598T3 (da) | Sulfonamidderivat og fremstillingsmetode og anvendelse deraf | |
| DK3255046T3 (da) | Hydroxyethylsulfonat af cyclin-afhængig proteinkinasehæmmer, krystallinsk form deraf og fremgangsmåde til fremstilling deraf | |
| DK3236934T3 (da) | Farmaceutisk sammensætning, fremstilling og anvendelser deraf |